<DOC>
	<DOCNO>NCT02979301</DOCNO>
	<brief_summary>The study examine whether change background parenchymal uptake ( BPU ) molecular breast imaging ( MBI ) induce short-term use low-dose tamoxifen . Women previously high BPU MBI recruit . Participants take low-dose tamoxifen 30-day period , post-tamoxifen MBI order investigate impact tamoxifen BPU .</brief_summary>
	<brief_title>MBI Response toTam</brief_title>
	<detailed_description />
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>The following requirement entry study : 1 . Female , age 40 old time enrollment 2 . Most recent MBI examination , perform within 3 year enrollment , show moderate mark background parenchymal uptake 3 . Mammogram perform within 12 month prior enrollment available comparison 4 . Willing able return MBI follow 30 day lowdose tamoxifen 5 . If able become pregnant 1 . Negative pregnancy test within 48 hour prior study MBI exam ( ) 2 . Agrees avoid pregnancy study least 2 month study participation end , abstinence , barrier method , nonhormonal contraception . 6 . Understands sign consent form Subjects exclude follow characteristic present : 1 ) Evidence suspect breast disease define positive finding recommendation shortinterval followup recent breast imaging ( include mammography , MBI , MRI , ultrasound , etc . ) yet resolve prior enrollment 2 ) Breast biopsy breast surgery perform 6 month prior enrollment 3 ) Bilateral breast implant status postbilateral prophylactic mastectomy 4 ) Pregnant lactate 5 ) Current recent use ( within 6 month prior enrollment ) follow drug : 1 . Systemic hormonal therapy ( oral transdermal patch formulation ) 2 . Hormonal contraception ( oral , transdermal , implanted , injected formulation ) 3 . Selective estrogen receptor modulators ( tamoxifen , raloxifene , toremifene ) 4 . Aromatase inhibitor ( anastrazole , letrozole , exemestane ) 5 . GnRH analogs 6 . Prolactin inhibitor 7 . Androgens antiandrogens 8 . Anticoagulants `` blood thinner '' ( warfarin , heparin , rivaroxaban novel anticoagulant ) 9 . Drugs know strong inhibitor CYP2D6 , major P450 enzyme metabolize tamoxifen , include : bupropion ( Wellbutrin ) fluoxetine ( Prozac ) paroxetine ( Paxil ) quinidine ( Quinidex ) 6 ) Personal history type malignancy , exclusion nonmelanoma skin cancer , diagnose prior enrollment 7 ) Personal history strong family history blood clot legs lung ( also know deep vein thrombosis pulmonary embolism ) 8 ) Personal history transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) 9 ) Active proliferative disorder endometrium atypical hyperplasia , history active endometriosis , unresected polyp 10 ) Any type retinal disorder severe cataract 11 ) Current former smoker 12 ) Known carrier BRCA1 BRCA2 genetic mutation know DNA repair defect .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>